–
1384
4
3
2
1*
D
30 - 35
.
.
44 .
I
of
ive
.
(20 mg/kg/day)
.
(YMRS)
(Remission)
12
ch
.
23
YMRS
.
.
:
DSM IV
(900 mg/day)
( Mixed
)
(20 mg/kg/day)
.
(Response)
Mann-Whitney Wilcoxon Fisher exact test
Ar
%50
(10-15 mg/day)
.
.
SI
.
:
YMRS
SPSS Ver11
.
p<0/05
21 27/18±7/34
44
:
( 17) %73/9
( 18)%85/7
( 10) %43/5
( 9)%42/9
(p<0/05)
.
:
I
.
:
.
0311 2222135 :
:
0913 3252576
-1
0311 2222135 :
Email: [email protected]
BMD(I)
-
-2
-3
-4
BMD(I)
.
(1 )
84/7/13 :
-1 2 3 4
84/5/20 :
www.SID.ir
2
.
(2 )
.
(
)
.
(
6)
DSMIV
(YMRS)
(11)
20
(3 )
( 4)
of
.
.
ive
.
.
.
(6 )
II
.
Ar
ch
I
.
.
SI
.
.
D
(10)
.
900
( 8)
(9 )
mEq/L
10-15
20
.
1
.
.
1384
–
www.SID.ir
2
53
27/18±7/34
23 (
)
+
.
(1)
)
.
21
.
.
.
.
D
.
%50
.
SI
.( p<0/05)
(Response)
(2)
12
.
.
CBC
(
.(p<0/05)
Mann-Whitney Wilcoxon, Fisher exact test
Ar
ch
.
0/515
0/01
0/04
0/21
0/18
P
0/211
0/217
0/46
0/31
1384
p<0/05
:1
II
(
)
SPSS11
(YMRS)
P
(Remission)
.
(YMRS)
.
10
(YMRS)
of
+
)
ive
(
44 (
I
)
(47/8)11
(78/3)18
(21/7)5
(0)0
(0)0
±
25/21±7/47
67/62±15/54
20/26±12/87
3/8±2/5
(
)
(38/1)8
(42/9)9
(42/9)9
(9/5)2
(4/8)1
±
28/04±7/28
62/23±12/20
17/76±7/78
3/6±2/8
(
(
)
)
(
(
)
)
–
www.SID.ir
2
:2
(YMRS)
2
1
+
+
±
±
31/4±7/31
28/08±8/81
20/45±10/88
14/29±14/29
32/4±8/55
27/09±10/48
18/23±11/20
15/22±11/60
0/19
0/84
0/845
0/395
0/930
0/404
-2/39±5/12
-10/90±8/47
-17/88±6/53
-7/36±5/72
-12/82±5/85
-4/64±3/37
-5/33±4/48
-14/19±7/36
-17/33±9/61
-8/85±5/67
-12/61±8/08
-3/11±6/73
)
(
1
+
)
(66/7)14
(9/5)2
(4/8)1
(0)0
(4/8)1
(4/8)1
(0)0
(4/8)1
(0)0
(0)0
(4/8)1
(0)0
(0)0
ch
ive
(60/9)14
(0)0
(4/3)1
(4/3)1
(4/3)1
(0)0
(4/3)1
(4/3)1
(4/3)1
(4/3)1
(0)0
(4/3)1
(4/3)1
Ar
0/98
0/68
0/97
0/92
0/96
0/92
0/94
0/96
0/94
0/94
0/87
0/87
0/89
(
%43/5
%42/9
Remission
(1)
.
.
(3)
%33/3
.
%31/9
0/64±0/18mEq/L 0/49 ±0/10mEq/L
%73/9
1384
)
:3
of
2
+
P
(
SI
0/69
0/73
0/51
0/80
D
P
%85/7 .
–
www.SID.ir
2
35
I
:46 =
30
.
: 46
%80
(13)
(YMRS)
25
\f/?4/ s3
20
15
Sachs
.
(14)
D
10
5
0/77 mEq/L
0
SI
1
.
P 39: =/
7
10
.
:1
ive
of
.
2
(16 15)
ch
.
.
(Multicentric)
Ar
.
I
:
.
I
.
.
(12)
References
1384
–
www.SID.ir
www.SID.ir
ive
ch
Ar
of
SI
D
2
1. Sadock BJ, Sadock VA. Kaplan & Sadocks
10. First MB, Spitzer RL, Gibbon M, Structured
comprehensive textbook of psychiatry. Lippincott
Clinical Interview for DSM-IV New York, NY:
Williams & Wilkins 2004; 1677.
Biometric
2. Woods SW. The economic burden of bipolar
disease. J Clin Psychiatry 2000; 61(Suppl 13):
38-41.
New
York
State
Psychiatric Institute; 1995.
11. Young RC, Biggs JT, Ziegler VE, Meyer DA.
A rating scale for mania: reliability, validity, and
Curlos A, Zarate JR, Jore A. Quivoz.
sensitivity. Br J Psychiatry 1978; 133: 429-435.
Combination treatment in bipolar disorder: a
12. Zajecka JM, Weisler R, Sachs G. A comparison
review of controlled trials. Bipolar disorders
of the Efficacy, safety and tolerability of
2003; 5(3): 217-225.
Divalproex
Initial lithium and valproate combination therapy
in acute mania. Neuropsychobiology 2002;
5. Reischeies FM,Harti Kanian J, Berghhofer AM.
Intitial triple therapy of acute mania, adding
13. Kowatch RA, Sethuraman G, Hume JH,
valproate
to
neuroleptics.
Pharmacopschiatry 2002; 35(6): 244-6.
Weinberg
WA.
Combination
pharmacotherapy in children and adolescents with
bipolar disorders. Biol Psychiaty 2003; 53(11):
978-84.
of
and
2002; 63(12): 1148-1155.
Kromelis,
46(Suppl 1): 22-7.
lithium
treatment of Bipolar disorder. J Clin Psychiatry
D
4. Reischeies FM, Hartikanian J, Berghofer A.
sodium and olanzapine in the
SI
3.
Research,
14. Sachs G, Chengappa KN, Suppes T, Mullen
JA, Brecher M, Devine NA, Sweitzer DE.
A, Bowden CL. Combination of a mood
Quetiapine with lithium or divalproex for the
stabilizer with risperidon or haloperidol for
treatment of bipolar mania: a randomized double-
treatment of acute mania: a double-blind,
blind, placebo-controlled study. Bipolar Disord
placebo-controlled comparison of efficacy and
2004; 16(3): 213-23.
ive
6. Sachs GS, Grossman F, Ghaemi SN, Okamato
ch
safety. Am J Psychiatry 2002; 159(7): 1146-54.
15. Melkersson KI, Hulting AL, Brismar KE.
Elevated of insulin, leptin, and blood lipids in
efficacy of atypical antipsychotics as add on
olanzapine-treated patients with schizophrenia or
therapy to mood stabilizers in the treatment of
related psychoses. J Clin Psychiatry 2000; 61:
Ar
7. Miller DS, Yathaqm LN, Lam RW. Comparative
acute mania.J Clinical Psychiatry 2001;975-80.
8. Yatham LN. Efficacy s of atypical antipsychotics
742-749.
16. Osser DN, Najarian DM, Dufresne RL.
in mood disorders. J Clin Psychopharmacol
Olanzapine
2003; 23(3 Suppl 1): 9-14.
triglyceride levels. J Clin Psychiatry 1999; 60:
9. Ghaemi SN. New treatment for bipolar disorder;
increases
weight
and
serum
767-770.
the role of atypical neuroleptic agents. J Clin
psychiatry 2000; 61(suppl 14): 33-42.
1384
–
www.SID.ir

Volunteer Roster 2014-2015